Would-be drug companies must either produce medicines that stand up to federal scrutiny, demonstrate that their data has value to other companies, or go out of business.
Alex Berenson (born January 6, 1973) is a former reporter for The New York Times and the author of several thriller novels and a book on corporate financial filings.[2]